Wells Fargo & Company Forecasts Strong Price Appreciation for Merck & Co., Inc. (NYSE:MRK) Stock

Key Points

• Wells Fargo raised its price target on Merck from $135 to $150 and maintained an "overweight" rating, implying about a 29% upside from the prior close.
• Merck beat quarterly expectations with Q EPS of $2.04 vs. $2.01 consensus and set FY2026 guidance of $5.00–$5.15 EPS, while analysts' consensus rating is a "Moderate Buy" with a $126.81 average target.
• Insider selling has been notable (320,176 shares worth ~$38.3M in the last 90 days) even as major institutions like Vanguard, State Street and Wellington increased stakes; institutional investors now own ~76% of the stock.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) had its target price raised by equities research analysts at Wells Fargo & Company from $135.00 to $150.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The brokerage currently has an "overweight" rating on the stock. Wells Fargo & Company's target price would suggest a potential upside of 29.07% from the stock's previous close.

Several other research analysts have also issued reports on the stock. TD Cowen increased their price target on shares of Merck & Co., Inc. from $100.00 to $120.00 and gave the stock a "hold" rating in a research report on Tuesday, January 20th. BMO Capital Markets raised Merck & Co., Inc. from a "market perform" rating to an "outperform" rating and lifted their price objective for the company from $82.00 to $130.00 in a report on Thursday, December 18th. Morgan Stanley upped their price objective on Merck & Co., Inc. from $100.00 to $102.00 and gave the company an "equal weight" rating in a research note on Friday, December 12th. Zacks Research cut Merck & Co., Inc. from a "hold" rating to a "strong sell" rating in a report on Friday, January 9th. Finally, Royal Bank Of Canada started coverage on Merck & Co., Inc. in a research note on Wednesday, February 25th. They issued an "outperform" rating and a $142.00 price target on the stock. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, six have given a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, Merck & Co., Inc. currently has an average rating of "Moderate Buy" and a consensus target price of $126.81.

Merck & Co., Inc. Stock Down 0.7%

MRK opened at $116.21 on Thursday. The company has a market capitalization of $287.32 billion, a P/E ratio of 15.96, a P/E/G ratio of 2.27 and a beta of 0.27. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.54 and a quick ratio of 1.30. The firm's fifty day moving average price is $114.86 and its two-hundred day moving average price is $99.26. Merck & Co., Inc. has a fifty-two week low of $73.31 and a fifty-two week high of $125.14.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last announced its quarterly earnings data on Tuesday, February 3rd. The company reported $2.04 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.01 by $0.03. The company had revenue of $16.40 billion during the quarter, compared to analysts' expectations of $16.19 billion. Merck & Co., Inc. had a net margin of 28.08% and a return on equity of 44.57%. The business's revenue was up 5.0% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.72 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. On average, analysts anticipate that Merck & Co., Inc. will post 9.01 EPS for the current year.

Insider Buying and Selling at Merck & Co., Inc.

In other Merck & Co., Inc. news, EVP Jennifer Zachary sold 121,573 shares of the business's stock in a transaction on Monday, February 9th. The stock was sold at an average price of $119.15, for a total value of $14,485,422.95. Following the transaction, the executive vice president owned 68,916 shares of the company's stock, valued at approximately $8,211,341.40. The trade was a 63.82% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Johannes Jacobus Oosthuizen sold 15,000 shares of the firm's stock in a transaction on Friday, February 6th. The shares were sold at an average price of $121.87, for a total value of $1,828,050.00. Following the completion of the sale, the insider owned 21,197 shares of the company's stock, valued at approximately $2,583,278.39. This trade represents a 41.44% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 320,176 shares of company stock worth $38,281,735 over the last 90 days. Company insiders own 0.13% of the company's stock.

Institutional Investors Weigh In On Merck & Co., Inc.

A number of hedge funds have recently added to or reduced their stakes in MRK. Vanguard Group Inc. lifted its holdings in Merck & Co., Inc. by 0.9% during the 4th quarter. Vanguard Group Inc. now owns 254,322,763 shares of the company's stock worth $26,770,014,000 after buying an additional 2,185,853 shares in the last quarter. State Street Corp increased its stake in shares of Merck & Co., Inc. by 1.6% in the 4th quarter. State Street Corp now owns 120,040,168 shares of the company's stock valued at $12,737,504,000 after buying an additional 1,859,990 shares during the period. Wellington Management Group LLP increased its stake in shares of Merck & Co., Inc. by 14.8% in the 4th quarter. Wellington Management Group LLP now owns 86,435,458 shares of the company's stock valued at $9,098,196,000 after buying an additional 11,156,354 shares during the period. Geode Capital Management LLC raised its position in shares of Merck & Co., Inc. by 0.4% during the fourth quarter. Geode Capital Management LLC now owns 60,047,984 shares of the company's stock worth $6,307,572,000 after acquiring an additional 249,110 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its position in shares of Merck & Co., Inc. by 9.4% during the second quarter. Charles Schwab Investment Management Inc. now owns 53,865,466 shares of the company's stock worth $4,263,991,000 after acquiring an additional 4,636,183 shares during the last quarter. Institutional investors own 76.07% of the company's stock.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.